Literature DB >> 24780392

Extracorporeal photopheresis in acute and chronic graft-versus-host disease.

Hildegard T Greinix1, Nina Worel2, Ulrike Just3, Robert Knobler3.   

Abstract

Graft-versus-host disease (GvHD) is a serious complication of allogeneic hematopoietic cell transplantation causing significant morbidity and mortality. Corticosteroids are the established first-line treatment of GvHD. Patients not responding to corticosteroids have a dismal prognosis. Extracorporeal photopheresis (ECP) has objective activity in the treatment of both acute and chronic corticosteroid-refractory GvHD patients, has an excellent safety profile and is internationally well-established. ECP has been recommended by a significant number of renowned scientific organizations as an efficient treatment option for patients with GvHD. ECP has a proven corticosteroid-sparing effect and favourably impacts on survival and quality of life of responding patients.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Extracorporeal photopheresis; Graft-versus-host disease

Mesh：

Year:  2014        PMID： 24780392     DOI： 10.1016/j.transci.2014.04.005

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN： 1473-0502            Impact factor:   1.764


  14 in total

1.  Shortened apheresis-based extra-corporeal photochemotherapy for acute refractory GVHD in children: a prospective study.

Authors:  A Sauret; N Rabiau; E Rochette; V Grèze; P Halle; M Ouachée; J-H Dalle; E Seror; D Serraz; K Yakouben; D Adjaoud; A Pagnier; A Marie-Cardine-Bobbia; C Oudot; C Curtillet; M Poirée; J Kanold; E Merlin
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

Review 2.  Extracorporeal photopheresis: cellular therapy for the treatment of acute and chronic graft-versus-host disease.

Authors:  Jennifer Schneiderman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease.

Authors:  Holly K Miller; Thomas M Braun; Terri Stillwell; Andrew C Harris; Sung Choi; James Connelly; Daniel Couriel; Steven Goldstein; Carrie L Kitko; John Magenau; Attaphol Pawarode; Pavan Reddy; Mary Riwes; Gregory A Yanik; John E Levine
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-22       Impact factor: 5.742

4.  Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.

Authors:  Kristin Baird; Leora E Comis; Galen O Joe; Seth M Steinberg; Fran T Hakim; Jeremy J Rose; Sandra A Mitchell; Steven Z Pavletic; William D Figg; Lawrence Yao; Kathleen C Flanders; Naoko Takebe; Stefanie Sarantopoulos; Susan Booher; Edward W Cowen
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-12       Impact factor: 5.742

5.  Deciphering the Mystery: Extracorporeal Photopheresis in Graft-versus-Host Disease.

Authors:  Annie Im; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-18       Impact factor: 5.742

6.  Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Authors:  R Zeiser; A Burchert; C Lengerke; M Verbeek; K Maas-Bauer; S K Metzelder; S Spoerl; M Ditschkowski; M Ecsedi; K Sockel; F Ayuk; S Ajib; F S de Fontbrune; I-K Na; L Penter; U Holtick; D Wolf; E Schuler; E Meyer; P Apostolova; H Bertz; R Marks; M Lübbert; R Wäsch; C Scheid; F Stölzel; R Ordemann; G Bug; G Kobbe; R Negrin; M Brune; A Spyridonidis; A Schmitt-Gräff; W van der Velden; G Huls; S Mielke; G U Grigoleit; J Kuball; R Flynn; G Ihorst; J Du; B R Blazar; R Arnold; N Kröger; J Passweg; J Halter; G Socié; D Beelen; C Peschel; A Neubauer; J Finke; J Duyster; N von Bubnoff
Journal:  Leukemia       Date:  2015-07-31       Impact factor: 11.528

Review 7.  Extracorporeal Photopheresis in Graft-versus-Host Disease.

Authors:  Beatrice Drexler; Andreas Buser; Laura Infanti; Gregor Stehle; Joerg Halter; Andreas Holbro
Journal:  Transfus Med Hemother       Date:  2020-05-19       Impact factor: 3.747

8.  Does Offline Beat Inline Treatment: Investigation into Extracorporeal Photopheresis.

Authors:  Wolfgang Helmberg; Sabine Sipurzynski; Andrea Groselje-Strehle; Hildegard Greinix; Peter Schlenke
Journal:  Transfus Med Hemother       Date:  2020-03-27       Impact factor: 3.747

9.  Higher response rates in patients with severe chronic skin graft-versus-host disease treated with extracorporeal photopheresis.

Authors:  Gabriel Afram; Emma Watz; Mats Remberger; Ulla Axdorph Nygell; Mikael Sundin; Hans Hägglund; Jonas Mattsson; Michael Uhlin
Journal:  Cent Eur J Immunol       Date:  2019-04-15       Impact factor: 2.085

10.  Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects.

Authors:  Lei Wang; Ming Ni; Angela Hückelhoven-Krauss; Leopold Sellner; Jean-Marc Hoffmann; Brigitte Neuber; Thomas Luft; Ute Hegenbart; Stefan Schönland; Christian Kleist; Martin Sill; Bao-An Chen; Patrick Wuchter; Volker Eckstein; William Krüger; Inken Hilgendorf; Ronit Yerushalmi; Arnon Nagler; Carsten Müller-Tidow; Anthony D Ho; Peter Dreger; Michael Schmitt; Anita Schmitt
Journal:  Front Immunol       Date:  2018-10-08       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.